Study on Tear Proteins in Diabetic Retinopathy of Type 2 Diabetics
This trial is active, not recruiting.
|Sponsor||Dow University of Health Sciences|
|Start date||January 2009|
|End date||December 2010|
|Trial size||350 participants|
|Trial identifier||NCT00698698, Tear proteins|
Diabetes mellitus is becoming a global epidemic. There is a need to devise a non invasive method for detection of diabetes and its related complication. Tear proteins are easy to collect causing no harm to a patient and different studies indicate that tear proteins of diabetic patients are significantly different from non diabetic population. This difference in the composition of tear proteins become more pronounced with advancement of diabetic retinopathy.
|Observational model||case control|
Male or female participants from 30 years up to 90 years old.
Inclusion Criteria: - diabetic patients with type 2 diabetes - age above 30 - willing to participate Exclusion Criteria: - ocular surface disorders. - collagen vascular diseases - Limbal hyperemia - previous ocular surgery - creatinine level above 1.0 - liver diseases
|Official title||Tear Proteins and Diabetic Retinopathy|
|Principal investigator||Dr. Jamshed Ahmed, FCPS|
|Description||Diabetes mellitus causes a significant alteration in tear proteins. If we analyze tear proteins by means of electrophoresis, HPLC, and mass spectroscopy. We can find different type of tear proteins in different grades of diabetic retinopathy these biomarkers can help in mass screening , diagnosis and management of diabetic population.|
Call for more information